Loading clinical trials...
Loading clinical trials...
A Prospective Observational Study in Cystic Fibrosis Patients With Chronic Respiratory Pseudomonas Aeruginosa Infection Treated With TOBI® PODHALER® (Tobramycin Inhalation Powder) or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
Conditions
Interventions
TOBI® PODHALER®
TOBI®
+2 more
Locations
47
United States
Novartis Investigative Site
Anchorage, Alaska, United States
Novartis Investigative Site
Little Rock, Arkansas, United States
Novartis Investigative Site
Bellflower, California, United States
Novartis Investigative Site
Fullerton, California, United States
Novartis Investigative Site
Los Angeles, California, United States
Novartis Investigative Site
Madera, California, United States
Start Date
May 5, 2015
Primary Completion Date
December 31, 2021
Completion Date
December 31, 2021
Last Updated
March 22, 2022
Lead Sponsor
Mylan Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions